Should VV ECMO be considered as treatment option in COVID-19 infection after kidney transplant? A word of caution.
Joao Roberto BredaBrandon Masi ParkerGiselle GuerraAkia DawsonMatthias LoebePublished in: Clinical transplantation (2023)
Several reports have shown that hospitalized kidney transplant recipients (KTR) had high mortality rates when infected with COVID-19. Extracorporeal Membrane Oxygenation (ECMO) has been shown to be an option for refractory respiratory failure in COVID-19 patients with variable rates of recovery. The outcome of ECMO in respiratory failure is highly related to cohort investigated and patient selection. Over a 10-month period in the height of COVID-19 pandemic 5 KTR patients were placed on ECMO with none of the patients surviving to discharge. All patients experienced multisystem organ failure (MSOF) and hematologic pathology while on ECMO. We concluded that COVID-19 in KTR patients presents with a refractory MSOF that is not well supported with ECMO in a traditional approach. Future work is needed to determine how to best support refractory respiratory failure in KTR patients with COVID-19.
Keyphrases
- extracorporeal membrane oxygenation
- respiratory failure
- acute respiratory distress syndrome
- end stage renal disease
- ejection fraction
- newly diagnosed
- sars cov
- coronavirus disease
- type diabetes
- peritoneal dialysis
- cardiovascular disease
- emergency department
- high resolution
- body mass index
- patient reported outcomes